Gardenia Blue has been submitted to the US FDA, EU EFSA for permission of use, and included in the FAO/WHO Joint Expert Committee on Food Additives (JECFA) priority list. The US FDA approved Gardenia Blue in July 2025, and an additional application will be submitted to expand the current permitted uses.
As a key component of the risk assessment, the Estimated Daily Intake (EDI) was calculated. The EDI evaluation used consumption data from the US, EU, UK, and Brazil, along with the CIFOCOss (Chronic Individual Food Consumption Database – Summary Statistics) developed by FAO/WHO and the commercial market database to adjust maximum use levels and estimate intake for model foods.
For the JECFA evaluation, the EDIs for Gardenia Blue were calculated based on food consumption data from multiple countries and model diets. The EDI on a Gardenia Blue Polymer basis was estimated by assuming a maximum content level of 40%.
Genotoxicity studies demonstrated that Gardenia Blue has no mutagenic or genotoxic potential. In chronic toxicity studies, the NOAEL was determined to be 2,175.3 mg/kg body weight/day. Based on the maximum EDI, a margin of exposure (MOE) greater than 100 was derived, indicating an adequate safety margin.
In the JECFA evaluation, the NOAEL for Gardenia Blue Polymer was determined to be 700 mg/kg body weight/day, and the Acceptable Daily Intake (ADI) was established at 0–7 mg/kg body weight/day. The safety of Gardenia Blue was confirmed based on the ADI and EDI assessments.
抄録全体を表示